This article was originally published in The Gray Sheet
Philips Healthcare clarifies that it has complied with FDA's Aug. 7 deadline for submitting safety and efficacy data for currently marketed pre-amendment device types. Philips markets the HeartStart home defibrillator and Q-CPR external compression device, which are both pre-amendment Class III devices cleared via 510(k). The data was submitted the week of Aug. 3, the company says, although it initially reported the week of Aug. 10 that it was still preparing its response (1"The Gray Sheet" Aug. 17, 2009)
You may also be interested in...
A friendly reminder to pre-amendments device makers: failing to submit the safety and effectiveness information FDA ordered on 25 device types this April could result in seizure, injunction or even criminal prosecution
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.